Pharma Commercial Mock

← All views·CI feed·API docs

ASCO

Meeting Library

ESMO Congress 2026 · Barcelona, Spain

Abstract 102872026-09-01 · 15:15 CT · Hall B1
Real-world effectiveness of Opdivo vs standard of care in metastatic melanoma
G. Curigliano, P. Schmid, S. Modi, et al. · Princess Margaret Cancer Centre
Rapid Oral Abstract SessionMelanoma📄🖼️🎬
Abstract 102692026-09-04 · 18:30 CT · Hall B1
Keytruda plus chemotherapy in previously untreated metastatic melanoma: updated analysis from KEYNOTE-603
E. Winer, A. Spira, F. Andre · Cleveland Clinic
Rapid Oral Abstract SessionMelanoma📄🖼️🎬
Abstract 103122026-09-02 · 15:15 CT · E450
KEYNOTE-167: Keytruda (pembrolizumab) neoadjuvant in metastatic melanoma
H. Borghaei, A. Spira, N. Rizvi, et al. · Stanford Cancer Institute
Rapid Oral Abstract SessionMelanoma📄🖼️🎬
Abstract 102032026-09-05 · 18:30 CT · S406
Real-world effectiveness of Keytruda vs standard of care in metastatic melanoma
G. Curigliano, S. Modi · Institut Gustave Roussy
Rapid Oral Abstract SessionMelanoma📄🖼️🎬
Abstract 102102026-09-04 · 21:45 CT · Hall B1
Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-161
E. Winer, M. Reck · University of Chicago
Rapid Oral Abstract SessionMelanoma📄🖼️🎬

⚠ Under embargo

Embargo lifts 2026-09-01 at 15:15 CT

Abstract 10287

Real-world effectiveness of Opdivo vs standard of care in metastatic melanoma

G. Curigliano¹, P. Schmid, S. Modi, M.C. Garassino, C. Robert

¹ Princess Margaret Cancer Centre (presenter)

Rapid Oral Abstract Session: Melanoma[view all in session]

2026-09-01 · 15:15 CT · Hall B1 · Sponsor: Bristol-Myers Squibb

Background: Despite the availability of immune checkpoint inhibitors, optimal first-line therapy for metastatic melanoma remains an open question. Opdivo (undefined) is a anti-PD-1 mAb.

Methods: III-phase, randomized trial (CheckMate-785, NCT91855031). Patients with metastatic melanoma were randomized to Opdivo or standard of care. Primary endpoint: overall survival.

Results: OS 65 months (HR 0.63, 95% CI 0.54-0.72, p0.002). PFS 13.7 months. ORR 55.2%.

Conclusions: Median OS 65 months. HR 0.63 (95% CI 0.54–0.72). Grade ≥3 AEs consistent with prior reports.

Clinical trial information: NCT91855031

Citation: J Clin Oncol 44, 2026 (suppl 17; abstr 10287). DOI: 10.1200/JCO.2026.44.17_suppl.10287

▸ Author disclosures

G. Curigliano: Consulting/advisory — Bristol-Myers Squibb; Research funding (institution) — Bristol-Myers Squibb.